HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Fenfluramine-like cardiovascular side-effects of benfluorex.

Abstract : Since 1976, benfluorex has been approved in Europe as a hypolipidemic and hypoglycemic drug, and is commonly used in the treatment of the metabolic syndrome. As a derivative of fenfluramine with an appetite suppressant action, benfluorex is preferentially used in overweight patients. In contrast to fenfluramine and dexfenfluramine, to date, benfluorex has not been reported to be associated with frequent cardiovascular side-effects. The present study reports five cases of severe pulmonary arterial hypertension and one case of valvular heart disease occurring in patients exposed to benfluorex. These individuals were middle age, diabetic females with a body mass index ranging 24.2-49 kg x m(-2). No definite causal effect for cardiovascular disease with benfluorex can be drawn from such case reports. However, as benfluorex, like dexfenfluramine and fenfluramine, is metabolised into active metabolite norfenfluramine, further extensive assessment of drug exposure in newly diagnosed pulmonary arterial hypertension or valvular heart disease patients is warranted.
Document type :
Journal articles
Complete list of metadata

Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Thursday, March 15, 2012 - 2:15:58 PM
Last modification on : Thursday, March 31, 2022 - 11:00:02 AM

Links full text



K. Boutet, Irène Frachon, Yannick Jobic, Christophe Gut-Gobert, Christophe Leroyer, et al.. Fenfluramine-like cardiovascular side-effects of benfluorex.. European Respiratory Journal, European Respiratory Society, 2009, 33 (3), pp.684-8. ⟨10.1183/09031936.00086308⟩. ⟨hal-00679313⟩



Record views